Human TROP-2 (trophoblast cell surface antigen 2) is a cell-surface type I transmembrane glycoprotein expressed in epithelial cells of various tissues. TROP-2 is also known as TROP2, TACSTD2, EGP-1, pancreatic carcinoma marker protein GA733–1/GA733, gastrointestinal tumor-associated antigen GA7331, GP50, M1S1, tumor-associated calcium signal transducer 2, CAA1, and TTD2. TROP-2 exists as a monomer on the cell surface but can form dimers or oligomers on cancer cells enhancing its role in cancer progression. TROP-2 contains an extracellular domain, a single transmembrane helix, and a cytoplasmic tail. The extracellular domain is comprised of three subdomains: a cysteine-rich domain, a thyroglobulin type-1 domain, and a cysteine-poor domain. TROP-2 is normally involved in the maintenance of epithelial tissue integrity. It is overexpressed in many cancers including breast cancer, non-small-cell lung cancer, thyroid cancer, gastric cancer, pancreatic cancer, and ovarian cancer. TROP-2 overexpression is involved in cancer cell growth, proliferation, invasion, migration, and survival of cancer cells, and is associated with tumor aggressiveness and poor prognosis. TROP-2 is an emerging target of cancer therapeutics.
MW: Molecular Weight marker reduced condition
NR: TROP-2 dimer under non-reducing condition
Immobilized TROP-2-Flag-His dimer protein (Cat. No. CSP-24041-02) at 2 μg/mL (100 μL/well) can bind anti-human TROP-2 monoclonal antibody with half maximal effective concentration (EC50) range of 10.9-43.6 ng/mL (QC tested).